Clinical trial NCT00604890: Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
Official title: Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Superficial Basal Cell Carcinoma
Keywords: Double-Blind
Placebo
Topical
Treatment
Dose-Ranging
sBCC
Lead sponsor: BPGbio
Sponsor class: INDUSTRY
First posted: 2008-01-30
Enrollment: 186
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the safety and tolerability of pharmaceutical compound (API 31510) topical cream topically applied to superficial basal cell carcinomas to obtain preliminary efficacy data for the treatment of superficial basal cell carcinomas by API 31510 topical cream. The study population will include one hundred and sixty (160) otherwise healthy male or female adults with one or more histologically confirmed superficial basal cell carcinoma lesions. One target lesion with an area of less than one inch will be designated for study treatment.


Eligibility criteria: Inclusion Criteria:

* Male or female adults ≥ 18 years of age
* Primary, histologically confirmed sBCC with a minimum area of 0.5 cm2 and with a maximum diameter of 2.0 cm target sBCC lesion suitable for excision
* Histological diagnosis made no more than 4 weeks prior to the screening visit
* Histological biopsy removed 25% or less of the target lesion
* No other dermatological disease in the sBCC target site or surrounding area
* Willing to refrain from using non-approved lotions or creams on the target site and surrounding area during the treatment period. Willing to refrain from washing the treated area for at least 8 hours following the application of study medication
* Willing to refrain from exposure to direct sunlight or ultraviolet light and to avoid the use of tanning parlors for the duration of the study
* Laboratory values for the tests listed in the Study Schedule on page 2 within the reference ranges as defined by the central laboratory, or "out of range" test results that are clinically acceptable to the investigator.
* Ability to follow study instructions and likely to complete all study requirements
* Written informed consent obtained, including consent for tissue to be examined and stored by the central dermatopathologist
* Written consent to allow photographs of the target sBCC lesion to be used as part of the study data
* For females of childbearing potential, a negative pregnancy test at screening and using an acceptable form of birth control (oral/implant/injectable/transdermal contraceptives, intrauterine device, condom, diaphragm, abstinence, or a monogamous relationship with a partner who has had a vasectomy)

Exclusion Criteria:

* Pregnant or lactating
* Presence of known or suspected systemic cancer
* Histological evidence of nBCC, SCC, or any other tumor in the biopsy specimen
* Histological evidence of severe squamous metaplasia, infiltrative, desomoplastic or micronodular growth patterns in the biopsy specimen
* History of recurrence of the target sBCC lesion
* Evidence of dermatological disease or confounding skin condition in the treatment area, e.g., SCC, actinic keratosis, rosacea, psoriasis, atopic dermatitis, eczema, xeroderma pigmentosa
* Concurrent disease or treatment that suppresses the immune system
* Chronic medical condition that in the judgment of the investigator(s) would interfere with the performance of the study or would place the patient at undue risk
* Known sensitivity to any of the ingredients in the study medication
* Use of a tanning parlor or other excessive or prolonged exposure to ultraviolet light or direct sunlight during the course of the study
* Treatment with systemic chemotherapeutic agents within the 6 months prior to the screening visit
* Use of systemic retinoids within the 6 months prior to the screening period
* Treatment with systemic immunomodulators or immunosuppressants within the 6 months prior to the screening period
* Use of topical immunomodulators within 2 cm of the target BCC lesion within the 4 weeks prior to the screening period
* Treatment with the following topical agents within the 4 weeks prior to the screening visit: levulanic acid, 5-fluorouracil, coricosteroids, retinoids, diclofenac, hyaluronic acid, imiquimod
* Undergone a facial resurfacing procedure, i.e., chemical peel, laser resurfacing, dermabrasion, within the 6 months prior to the screening visit, if the target sBCC lesion is on the face
* Treatment with liquid nitrogen, surgical excision or curettage within 2 cm of the target sBCC lesion during the 4 weeks prior to the screening visit
* Elective surgery within 4 weeks prior to the screening visit, during the study, or 4 weeks after the treatment period
* Evidence of current chronic alcohol or drug abuse
* Current enrollment in an investigational drug or device study or participation in such a study within 4 weeks of the screening visit
* In the investigator's opinion, evidence of unwillingness, or inability to follow the restrictions of the protocol and complete the study

Primary outcomes:
measure: Number of Participants With Complete Response
timeFrame: 10 weeks
Secondary outcomes:
measure: Number of Participants With Partial Response
timeFrame: 10 weeks
Other outcomes:
Locations:
city: Hot Springs
country: United States
facility: Burke Pharmaceuticals
state: Arkansas
city: San Diego
country: United States
facility: Skin Surgery Medical Group, Inc.
state: California
city: Denver
country: United States
facility: Colorado Medical Research Center
state: Colorado
city: Coral Gables
country: United States
facility: Dermatology Associates and Research
state: Florida
city: Snellville
country: United States
facility: Gwinnett Clinical Research
state: Georgia
city: Buffalo Grove
country: United States
facility: Scott D. Glazer, M.D., S.C.
state: Illinois
city: Champaign
country: United States
facility: Christie Clinic
state: Illinois
city: Smithtown
country: United States
facility: Long Island Skin Cancer and Dermatologic Surgery, PC
state: New York
city: Portland
country: United States
facility: Oregon Dermatology and Research Center
state: Oregon
city: San Antonio
country: United States
facility: Dermatology Clinical Research Center of San Antonio
state: Texas
city: Lynchburg
country: United States
facility: Education & Research Foundation
state: Virginia
Study officials:
affiliation: Education and Research Foundation
name: David Wilson, MD
role: PRINCIPAL_INVESTIGATOR
References: